Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the conditions precedent of the Subscription as set out in the Subscription Agreement have been fulfilled. Completion of Subscription took place on 19 December 2018 whereby the Subscription Shares were allotted and issued to the Subscriber in accordance with the terms and conditions of the Subscription Agreement.

Reference is made to the announcement of Yestar Healthcare Holdings Company Limited (the "**Company**") dated 30 November 2018 (the "**Announcement**") in relation to, among others, the Subscription of new Shares under the General Mandate. Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise stated.

COMPLETION OF THE SUBSCRIPTION

The Board is pleased to announce that all the conditions precedent of the Subscription as set out in the Subscription Agreement have been fulfilled. Completion of Subscription took place on 19 December 2018 whereby the Subscription Shares were allotted and issued to the Subscriber in accordance with the terms and conditions of the Subscription Agreement at the Subscription Price of HK$1.79 per Subscription Shares.

The approval of the listing of, and permission to deal in, the Subscription Shares has been granted by the Listing Committee of the Stock Exchange.

The proceeds from the Subscription have been satisfied by the Subscriber. The net proceeds received from the Subscription are approximately HK$409.7 million, which are intended to be used for general corporate purposes including (i) as to HK$163.88 million or 40% for possible acquisition on yet to identify target to expand the Group's market share; (ii) as to HK$163.88 million or 40% for repayment of interest bearing borrowings; and (iii) as to HK$81.94 million or 20% for the general working capital.

Pursuant to the Subscription Agreement, 230,000,000 Subscription Shares, representing approximately 9.56% of the issued share capital of the Company as at the date of this announcement, have been allotted and issued by the Company to the Subscriber at the Subscription Price of HK$1.79 per Subscription Share under the General Mandate. To the best of the Directors' knowledge, information and belief, and having made all reasonable enquiries, the Subscriber and its ultimate substantial beneficial owners as publicly disclosed at https://www.fujifilmholdings.com are Independent Third Parties.

CHANGES IN SHAREHOLDING STRUCTURE

The shareholding structure of the Company before and immediately after the Completion of the Subscription are summarized as follows:

Shareholders	**Before the Completion of the Subscription**		**Immediately after the Completion of the Subscription**	
	Number of Shares	%	*Number of Shares*	%
Director				
Hartono James	546,090,000 (Note 1)	25.11%	546,090,000 (Note 1)	22.70%
Substantial shareholder				
Hartono Jeane	459,370,000	21.12%	459,370,000	19.10%
Hartono Rico	265,810,000	12.22%	265,810,000	11.05%
Hartono Chen Chen Irene	119,475,000	5.49%	119,475,000	4.97%
Li Bin	164,600,600	7.57%	164,600,600	6.85%
Public shareholder				
Subscriber	—	—	230,000,000	9.56%
Other public Shareholders	619,854,400	28.49%	619,854,400	25.77% (Note 2)
Total	**2,175,200,000**	**100.00%**	**2,405,200,000**	**100.00%**

Notes:

1. Out of the 546,090,000 Shares, 20,000,000 Shares were beneficially owned by Amrosia Investments Limited, a company wholly-owned by Mr. Hartono James.

2. The above percentage figures are subject to rounding adjustments. Accordingly, figures shown as total may not be an arithmetic aggregation of the figures preceding it.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Shanghai, 19 December 2018

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Tirtamarta Karsono (Kwee Yoe Chiang) and Mr. Sutikno Liky.